Physician profile
Sunto Yen
NPI 1255610937
$7,339.68
in general payments reported to CMS, 2019-2025
33 companies · $1,021 in 2025
The $1,021 reported for 2025 was more than what 88% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $274 · 2020: $915 · 2021: $1,503 · 2022: $1,309 · 2023: $1,033 · 2024: $1,286 · 2025: $1,021.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,339.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,339.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,358.77 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $963.41 | 2021-2025 | Relistor |
| Amarin Pharma, INC. | $816.22 | 2020-2023 | |
| Novartis Pharmaceuticals Corporation | $655.70 | 2019-2025 | |
| Novo Nordisk INC | $573.50 | 2019-2025 | Rybelsus, Ozempic |
| Merck Sharp & Dohme LLC | $410.35 | 2021-2025 | Verquvo |
| Abbvie INC. | $298.07 | 2021-2024 | Ubrelvy |
| Pfizer INC. | $251.40 | 2023-2025 | |
| Glaxosmithkline, LLC. | $203.35 | 2019-2021 | |
| Xeris Pharmaceuticals, INC. | $199.47 | 2023-2025 | Gvoke Hypopen |
| Ibsa Pharma INC. | $182.18 | 2021-2024 | Tirosint, Licart, Tirosint |
| Avanos Medical | $147.05 | 2022-2025 | Genvisc 850 Sodium Hyaluronate |
| Scilex Pharmaceuticals INC. | $145.85 | 2019-2024 | |
| Redhill Biopharma INC. | $135.26 | 2020-2021 | |
| Horizon Therapeutics Plc | $132.75 | 2019-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $124.38 | 2021-2025 | Nexletol |
| Biohaven Pharmaceutical Holding Company LTD. | $116.83 | 2022 | |
| Amgen INC. | $87.04 | 2019-2025 | Krystexxa |
| Koya Medical, INC. | $70.83 | 2024 | Dayspring, Koya Medical |
| Medtronic, INC. | $63.64 | 2025 | Venaseal |
| Biohaven Pharmaceuticals, INC. | $63.58 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $58.41 | 2019-2025 | Eliquis |
| Qol Medical, LLC | $44.38 | 2021 | |
| Exact Sciences Corporation | $37.94 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Hikma Pharmaceuticals USA | $34.94 | 2019-2022 | |
| Depuy Synthes Sales INC. | $33.78 | 2023-2024 | Monovisc, Orthovisc |
| Allergan, INC. | $31.92 | 2020 | |
| Azurity Pharmaceuticals, INC. | $24.60 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.93 | 2019 | |
| Orthogenrx INC. | $16.38 | 2021 | |
| Pacira Therapeutics, INC. | $14.24 | 2020 | |
| Valinor Pharma, LLC | $14.19 | 2025 | Movantik |
| Boston Scientific Corporation | $11.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sunto Yen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.